Iovance Biotherp Stock Price, News & Analysis

Iovance (NASDAQ: IOVA) reported Q3 2025 product revenue of ~$68 million (up 13% QoQ) with gross margin of 43% and cost of sales of ~$39 million. Cash, investments, and restricted cash totaled ~$307 million as of Sept 30, 2025, projected to fund operations into Q2 2027. The company reaffirmed full‑year 2025 revenue guidance of $250–$300 million. Commercial updates: >80 U.S. authorized treatment centers, ~95% of patients within a two‑hour drive, and manufacturing turnaround of 32 days. Regulatory and pipeline: Health Canada approval for Amtagvi (Aug 2025) and positive lifileucel data in nonsquamous NSCLC (ORR 26%; mDOR not reached at >25 months); enrollment and registrational trials planned through 2026–2027.

Iovance (NASDAQ: IOVA) reported interim registrational Phase 2 IOV-LUN-202 data for lifileucel in previously treated advanced nonsquamous NSCLC: an objective response rate (ORR) of 25.6% (10/39 patients), including 2 complete responses, and a disease control rate of 71.8%. The median duration of response was not reached after a median follow-up of 25.4 months. The FDA gave positive regulatory feedback on trial design and potency assays. Iovance expects to progress toward a supplemental BLA in 2026 with a potential commercial launch in H2 2027. Safety trends improved after a reduced lymphodepletion regimen, with shorter post-IL-2 hospital stays.

Iovance Biotherapeutics (NASDAQ: IOVA) will report third quarter 2025 financial results and corporate updates before market on Thursday, November 6, 2025. Management will host a conference call and live audio webcast on November 6, 2025 at 8:30 a.m. ET to discuss results and provide a corporate update.

Investors can register to listen live or access the archived audio webcast at https://edge.media-server.com/mmc/p/pg9qgz86 or via the Investors section of the company website IR.Iovance.com. The archived webcast will be available for one year.

Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock option grants on October 16, 2025 covering an aggregate of 62,790 shares of common stock for nine new non-executive employees under its Amended and Restated 2021 Inducement Plan.

Each option has an exercise price of $2.24 (closing price on the Date of Grant) and vests over three years: one-third at the first anniversary of each employee’s start date and the remainder in eight quarterly installments thereafter, subject to continued employment. Grants were made pursuant to Nasdaq Listing Rule 5635(c)(4).

Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company specializing in TIL therapies for cancer patients, has granted inducement stock options to two new non-executive employees. The grants, approved on September 18, 2025, cover 22,810 shares of common stock with an exercise price of $2.20 per share.

The stock options were awarded under Iovance's Amended and Restated 2021 Inducement Plan, which follows Nasdaq Listing Rule 5635(c)(4). The options vest over three years, with one-third vesting on the first employment anniversary and the remaining portions vesting quarterly over the following two years.

Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company specializing in tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has announced its participation in two upcoming investor conferences.

The company will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 5, 2025, at 8:00 a.m. ET in Boston, MA. Additionally, Iovance will deliver a presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 11:00 a.m. ET in New York, NY.

Investors can access both live and archived webcasts of these presentations through the company's investor relations website.

Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company specializing in TIL cancer therapies, has announced inducement grants under NASDAQ Listing Rule 5635(c)(4). The company approved stock options for 182,370 shares to 20 new non-executive employees on August 21, 2025.

The stock options, granted under Iovance's Amended and Restated 2021 Inducement Plan, have an exercise price of $2.54 per share. The vesting schedule spans three years, with one-third vesting after the first year and the remaining portions vesting quarterly over the following two years.

Iovance Biotherapeutics (NASDAQ: IOVA) has achieved a significant milestone as Health Canada approved Amtagvi® (lifileucel) for treating advanced melanoma. This marks the first T cell therapy approved for solid tumor cancer in Canada and the company's first marketing authorization outside the U.S.

Amtagvi is specifically indicated for adult patients with unresectable or metastatic melanoma who have progressed after prior systemic therapy, including PD-1 blocking antibody and BRAF/MEK inhibitors where applicable. The approval was granted under Notice of Compliance with Conditions (NOC/c) based on the global C-144-01 trial results, pending confirmation of clinical benefits.

The company plans to authorize its first Canadian treatment center within the next few months and is pursuing expansion into additional markets.

Iovance Biotherapeutics (NASDAQ: IOVA) reported strong Q2 2025 financial results, with total product revenue of $60.0M, a 93% year-over-year increase. The company's flagship product Amtagvi generated $54.1M in revenue, with over 100 patients treated in Q2. The company reiterated its FY25 total product revenue guidance of $250M-$300M.

Key developments include a strategic restructuring expected to save over $100M annually and extend cash runway into Q4 2026, a real-world study showing 48.8% objective response rate for Amtagvi, and expansion of treatment centers to 80+ U.S. locations across 35 states. The company maintains a strong cash position of $307.1M as of June 30, 2025.

Pipeline progress includes ongoing trials in melanoma, NSCLC, and endometrial cancer, with several regulatory milestones expected in key markets including Canada, UK, and Australia.